These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 9649695

  • 1. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma.
    Andrès P, Cupissol D, Guillot B, Avril MF, Drèno B.
    Eur J Dermatol; 1998 Jun; 8(4):235-9. PubMed ID: 9649695
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study.
    Schmidt H, Geertsen PF, Fode K, Rytter C, Bastholt L, von der Maase H.
    Melanoma Res; 2000 Feb; 10(1):66-77. PubMed ID: 10711642
    [Abstract] [Full Text] [Related]

  • 4. [Combination of dacarbazine, cisplatin and interferon alpha in the treatment of metastatic melanoma].
    Tessier MH, Mansat E, Legoux B, Litoux P, Dreno B.
    Ann Dermatol Venereol; 1996 Feb; 123(9):538-42. PubMed ID: 9615103
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Treatment of metastasized malignant melanoma].
    Kamanabrou D.
    Praxis (Bern 1994); 2001 Mar 08; 90(10):391-6. PubMed ID: 11305184
    [Abstract] [Full Text] [Related]

  • 7. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L, Fiorentini G, Guida M, Michiara M, Freschi A, Aitini E, Ballardini M, Bichisao E, Ridolfi R, Italian Melanoma Intergroup.
    Melanoma Res; 2009 Apr 08; 19(2):100-5. PubMed ID: 19262411
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
    Thompson JA, Gold PJ, Fefer A.
    Semin Oncol; 1997 Feb 08; 24(1 Suppl 4):S44-8. PubMed ID: 9122734
    [Abstract] [Full Text] [Related]

  • 11. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
    Hofmann MA, Sterry W, Trefzer U.
    Jpn J Clin Oncol; 2007 Mar 08; 37(3):224-9. PubMed ID: 17472972
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB.
    J Clin Oncol; 2003 Jul 01; 21(13):2564-73. PubMed ID: 12829677
    [Abstract] [Full Text] [Related]

  • 13. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero JM, Mayeur D, Rixe O, Sun XS, Bernard O, Andre T, Tournigand C, Muracciole X, Guilhot J, Subcutaneous Administration Propeukin Program Cooperative Group.
    J Clin Oncol; 2003 Nov 01; 21(21):3987-94. PubMed ID: 14581421
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A, Delva R, Gomez F, Chevreau C, Douillard JY, Peny J, Coudert B, Négrier S, Groupe Français d'Immunothérapie.
    Cancer; 2002 Dec 01; 95(11):2324-30. PubMed ID: 12436438
    [Abstract] [Full Text] [Related]

  • 16. Interleukin-2 plus chemotherapy for patients with metastatic melanoma.
    Paciucci PA, Ryder JS, Mandell JP, Morris JC, Holland JF.
    Melanoma Res; 2000 Jun 01; 10(3):291-5. PubMed ID: 10890384
    [Abstract] [Full Text] [Related]

  • 17. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W.
    Br J Cancer; 2001 Apr 20; 84(8):1036-42. PubMed ID: 11308250
    [Abstract] [Full Text] [Related]

  • 18. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
    Bedikian AY, Johnson MM, Warneke CL, McIntyre S, Papadopoulos N, Hwu WJ, Kim K, Hwu P.
    J Immunotoxicol; 2008 Apr 20; 5(2):201-7. PubMed ID: 18569391
    [Abstract] [Full Text] [Related]

  • 19. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
    Legha SS.
    Semin Oncol; 1997 Feb 20; 24(1 Suppl 4):S39-43. PubMed ID: 9122733
    [Abstract] [Full Text] [Related]

  • 20. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
    Culine S, Iborra F, Mottet N, Avancès C, de Graeve B, Volpé P, Vignoud J, Bringer JP, Marroncle M, Le Pellec L, Ayuso D, Jansen E, Faix A, Rebillard X.
    Am J Clin Oncol; 2006 Apr 20; 29(2):148-52. PubMed ID: 16601433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.